GleamWall
中文EN

OTLK Outlook Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1649989 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-40.7%
TTM EPS YoY16.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin195.6%
Operating margin4,781.8%
Net margin5,253.5%
FCF margin—
EBITDA margin4,772.9%

Returns

ROE—
ROA-251.7%
ROIC (approx.)—
Asset turnover-0.05x

Leverage & solvency

Liabilities / assets139.7%
Debt / equity—
Current ratio0.81x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-20.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-06-302026Q2*2026-03-312026Q1*2025-12-312025Q4*2025-09-302025Q32025-06-302025Q22025-03-312025Q12024-12-312024Q4*2024-09-30
Income statement
Revenue$8,700$127,439-$1.21M-$91,787$1.51M———
Cost of revenue$16,965$149,327$29,626$916,515$439,815———
Gross profit-$8,265-$21,888-$1.24M-$1.01M$1.07M———
R&D expense$3.25M$4.50M$3.63M$5.98M$7.13M$4.41M$9.66M$12.52M
SG&A expense$7.55M$9.50M$8.61M$10.33M$9.68M$7.98M$11.95M$10.35M
Operating income-$10.81M-$14.03M-$13.48M-$17.31M-$15.75M-$12.39M-$21.61M-$22.88M
Interest expense———————$0
Pretax income-$20.32M-$4.45M—-$14.85M-$20.15M-$46.35M—$5.69M
Income tax———-$1.55M$0$2,800—$0
Net income-$20.32M-$4.45M-$23.06M-$13.29M-$20.15M-$46.36M$17.38M$5.69M
EBITDA-$10.80M-$14.00M-$13.45M-$17.28M-$15.72M-$12.36M-$21.58M-$22.85M
EPS (basic)-0.15-0.05-0.38—-0.55-1.500.72—
EPS (diluted)-0.15-0.05-0.38—-0.55-1.500.72—
Weighted avg. shares (diluted)136.74M81.84M60.21M—36.96M30.87M24.23M—
Banking
Net interest income$7$3$0-$264,156-$49,351-$18,502$48,881-$666,199
Balance sheet
Cash & equivalents$11.24M$7.75M$8.68M$8.08M$8.90M$7.56M$5.70M$14.93M
Receivables$1.64M$2.72M$114,609$1.49M$1.75M———
Inventory$5.04M$3.34M$3.46M$3.34M$4.13M$3.60M$3.11M—
Current assets$23.17M$20.90M$17.17M$17.39M$21.10M$17.81M$15.67M$27.42M
Total assets$26.18M$21.89M$18.24M$18.58M$22.39M$19.08M$17.01M$28.82M
Current liabilities$28.68M$38.88M$49.06M$45.81M$31.49M$24.82M$48.24M$42.55M
Total liabilities$36.58M$50.89M$56.79M$50.77M$59.58M$51.54M$67.30M$101.90M
Shareholders' equity-$10.39M-$28.99M-$38.55M-$32.19M-$37.19M-$32.46M-$50.29M-$73.08M
Shares outstanding187.10M104.61M64.56M53.89M43.48M32.91M24.91M23.91M
Cash flow statement
Operating cash flow-$21.01M-$7.83M-$14.94M-$12.38M-$11.90M-$16.58M-$10.97M-$16.98M
Financing cash flow$26.60M$6.90M$15.53M$11.56M$13.25M$18.44M$1.74M-$114,954
Depreciation & amortization$13,791$30,417$30,074$29,737$29,412$29,102$28,801$28,797
Stock-based compensation$791,671$757,483$881,150$1.82M$1.67M$1.70M$3.67M$1.41M

Free plan shows the latest 8 periods; Pro shows all 46 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.